Xpovio Use In Pregnancy & Lactation

Women of childbearing potential/Contraception in males and females: Women of childbearing potential should be advised to avoid becoming pregnant or abstain from sexual intercourse while being treated with selinexor and for at least 1 week following the last dose of selinexor. A pregnancy test is recommended for women of childbearing potential prior to initiating selinexor treatment.
Women of childbearing potential and male patients of reproductive potential should be advised to use effective contraceptive measures or abstain from sexual activity to prevent pregnancy during treatment with selinexor and for at least 1 week following the last dose of selinexor.
Pregnancy: There are no data from the use of selinexor in pregnant women. Studies in animals have shown selinexor can cause foetal harm (see Pharmacology: Toxicology: Preclinical safety data under Actions). Selinexor is not recommended during pregnancy and in women of childbearing potential not using contraception.
If the patient becomes pregnant while taking selinexor, selinexor should be immediately discontinued, and the patient should be apprised of the potential hazard to the foetus.
Breast-feeding: It is unknown whether selinexor or its metabolites are excreted in human milk. A risk to breast-fed children cannot be excluded. Breast-feeding should be discontinued during treatment with selinexor and for 1 week after the last dose.
Fertility: Based on findings in animals, selinexor may impair fertility in females and males (see Pharmacology: Toxicology: Preclinical safety data under Actions).